Bolt Biotherapeutics reported first-quarter 2026 results marked by ongoing clinical trial refinements for lead candidate BDC-4182, including introducing a step-up dosing regimen that delays initial data readouts to Q3 2026. The company continues to manage its cash burn by implementing a significant workforce reduction completed by the end of 2025, aiming to preserve capital into 2027. While Bolt’s proprietary Boltbody™ ISAC platform distinguishes its immuno-oncology pipeline, operational progress and liquidity remain tightly linked to clinical milestones and prudent cost control.